Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 5/20 | 0.67 |
| ▸ | CRBN | Q96SW2 | 10/20 | 0.65 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.65 |
| ▸ | CA2 | P00918 | 2/20 | 0.64 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.63 |
| ▸ | IDO1 | P14902 | 1/20 | 0.57 |
| ▸ | BCL2 | P10415 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | TNF | P01375 | 1/20 | 0.55 |
| ▸ | IL1B | P01584 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.55 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19453139 | 1.00 | STAT3 (0.67) | STAT3CRBNDDB1CA2DYRK2 | |
| SCHEMBL29658250 | 1.00 | STAT3 (0.67) | STAT3CRBNDDB1CA2DYRK2 | |
| SCHEMBL20305742 | 1.00 | STAT3 (0.67) | STAT3CRBNDDB1CA2DYRK2 | |
| SCHEMBL30312821 | 1.00 | STAT3 (0.67) | STAT3CRBNDDB1CA2DYRK2 | |
| SCHEMBL29658244 | 1.00 | STAT3 (0.67) | STAT3CRBNDDB1CA2DYRK2 | |
| SCHEMBL19475751 | 1.00 | STAT3 (0.67) | STAT3CRBNDDB1CA2DYRK2 | |
| SCHEMBL19475684 | 0.99 | CRBN (0.66) | STAT3CRBNDDB1CA2DYRK2 | |
| SCHEMBL29362368 | 0.99 | CRBN (0.66) | STAT3CRBNDDB1CA2DYRK2 | |
| SCHEMBL26813299 | 0.98 | STAT3 (0.65) | STAT3CRBNDDB1CA2DYRK2 | |
| SCHEMBL26813160 | 0.97 | STAT3 (0.64) | STAT3CRBNDDB1CA2DYRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250312462-A1 | PAK1 DEGRADERS AND METHODS OF USE THEREOF | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2025-10-09 | — | — | US | disclosed |
| EP-3743069-B1 | BCL-2 PROTEINS DEGRADERS FOR CANCER TREATMENT | BIOVENTURES LLC (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-4522158-A2 | PAK1 DEGRADERS AND METHODS OF USE THEREOF | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250073218-A1 | NLRP3 PROTEIN DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2025-03-06 | — | — | US | disclosed |
| WO-2025034789-A1 | ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK DEGRADERS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2025-02-13 | — | — | WO | disclosed |
| US-12118414-B2 | BCL-2 proteins degraders for cancer treatment | BIOVENTURES, LLC (US) | 2024-10-15 | — | — | US | disclosed |
| WO-2024108009-A1 | DYRK/CLK PROTACS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024108009-A1 | DYRK/CLK PROTACS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-05-23 | — | — | WO | disclosed |
| CN-112105360-B | BCL-2 protein degrading agent for cancer treatment | 生物风险投资有限责任公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20220017510-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2022-01-20 | — | — | US | disclosed |
| US-11161842-B2 | Bifunctional molecules for degradation of EGFR and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3445357-B1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2021-05-26 | — | — | EP | disclosed |
| CN-112105360-A | BCL-2 protein degrading agents for cancer treatment | 生物风险投资有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
| EP-3743069-A1 | BCL-2 PROTEINS DEGRADERS FOR CANCER TREATMENT | BioVentures, LLC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20200102298-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-02 | — | — | US | disclosed |
| US-10450310-B2 | Bifunctional molecules for degradation of EGFR and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| WO-2019144117-A1 | BCL-2 PROTEINS DEGRADERS FOR CANCER TREATMENT | BIOVENTURES, LLC (US) | 2019-07-25 | — | — | WO | disclosed |
| US-20190106417-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-11 | — | — | US | disclosed |
| WO-2017185036-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA FARBER CANCER INSTITUTE, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106417-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | EGFR, ERBB2, ERBB3 | STAT3 3043/4885CRBN 157/4885DDB1 404/4885 |
| US-20220017510-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | EGFR, ERBB2, ERBB3 | STAT3 3043/4885CRBN 157/4885DDB1 404/4885 |
| US-12118414-B2 | BCL-2 proteins degraders for cancer treatment | BCL2, BCL2L1, BCL2L2 | STAT3 1387/4885CRBN 263/4885DDB1 163/4885 |
| US-20250073218-A1 | NLRP3 PROTEIN DEGRADATION INDUCING COMPOUND | NLRP3, XIAP, NLRP1 | STAT3 1448/4885CRBN 365/4885DDB1 304/4885 |
| US-20200102298-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | EGFR, ERBB2, ERBB3 | STAT3 3043/4885CRBN 157/4885DDB1 404/4885 |
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, CRKL, OSTC | STAT3 4380/4885CRBN 39/4885DDB1 2712/4885 |
| US-11161842-B2 | Bifunctional molecules for degradation of EGFR and methods of use | EGFR, ERBB2, ERBB3 | STAT3 3043/4885CRBN 157/4885DDB1 404/4885 |
| US-20250312462-A1 | PAK1 DEGRADERS AND METHODS OF USE THEREOF | PAK1, PAK2, PAK6 | STAT3 3029/4885CRBN 1044/4885DDB1 938/4885 |
| US-10450310-B2 | Bifunctional molecules for degradation of EGFR and methods of use | EGFR, ERBB2, ERBB3 | STAT3 3043/4885CRBN 157/4885DDB1 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.